The role of the androgen receptor in prostate cancer-induced platelet aggregation and platelet-induced invasion.

Journal of Thrombosis and Haemostasis : JTH
Jan K RudzinskiPaul Jurasz

Abstract

Metastatic prostate cancer progresses from a hormone sensitive androgen receptor expressing phenotype to a hormone insensitive androgen receptor-independent subtype with low overall survival. Human platelets contribute to metastasis via tumor cell-induced platelet aggregation, which in part enhances cancer cell invasion. Given the more aggressive nature of hormone insensitive prostate cancer, we hypothesized that androgen receptor-negative prostate cancer cells exhibit higher platelet aggregation potency and invasive response compared to cells with androgen receptor. To characterize the role of androgen receptors in prostate cancer-induced platelet aggregation and platelet-induced invasion. Tumor cell-induced platelet aggregation experiments were performed with platelets from healthy human donors and benign prostate (RWPE-1) and prostate cancer cell lines positive (LNCaP) and negative for androgen receptor (DU145 and PC3). Immunoblot measured prostate cancer prothrombin. Modified Boyden chamber invasion assays and zymography were performed to assess the effects of platelets on prostate cancer cell invasion and matrix metalloproteinase (MMP) expression, respectively. Androgen receptor-positive prostate cancer cell lines failed t...Continue Reading

References

May 15, 1983·Thrombosis Research·M Radomski, S Moncada
Dec 6, 1994·Proceedings of the National Academy of Sciences of the United States of America·J S RhimG Jay
Oct 1, 1995·Scandinavian Journal of Gastroenterology·E HeinmöllerR J Weinel
Apr 1, 1996·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M W SwaimT F Huang
Mar 15, 2001·Proceedings of the National Academy of Sciences of the United States of America·L BorsigA Varki
Dec 24, 2003·British Journal of Pharmacology·David Alonso-EscolanoMarek W Radomski
Jun 3, 2004·Cancer Letters·Xin Tong, Honglin Li
Dec 8, 2004·Steroids·Marisa CabezaGuillermo Ceballos
Jul 30, 2005·Journal of Cellular Biochemistry·Kwanchanit TantivejkulKenneth J Pienta
Oct 26, 2005·Journal of Thrombosis and Haemostasis : JTH·E FalcinelliP Gresele
Jan 21, 2006·The Journal of Pharmacology and Experimental Therapeutics·Carlos MedinaMarek W Radomski
Apr 7, 2006·Journal of Cellular Biochemistry·Zoran Culig, Georg Bartsch
Apr 18, 2006·The Journal of Pharmacology and Experimental Therapeutics·David Alonso-EscolanoMarek W Radomski
Dec 23, 2008·International Journal of Cancer. Journal International Du Cancer·Olga DashevskyAlexander Brill
Aug 28, 2010·Cancer Biology & Therapy·Karen DeFeoSusan K Gilmour
Dec 21, 2010·Cancer Investigation·Manish KohliWilliam A Ricke
Jul 13, 2013·Science·John T Isaacs
Sep 19, 2015·Cancer Biology & Therapy·Eric T AlexanderSusan K Gilmour
Feb 14, 2017·Journal of Biological Methods·Natasha GovindasamyPaul Jurasz
May 16, 2018·The Prostate·Hassan A Al SalehKhalid Al-Nedawi
May 23, 2018·Journal of the National Comprehensive Cancer Network : JNCCN·Peter H Carroll, James L Mohler

❮ Previous
Next ❯

Related Concepts